129297-31-0

Upstream product

• 120008-91-5 ethyl 7-(1-benzyloxycarbonyl-4-piperidyl)-2-chloroheptanoate 
• 63628-63-7 Nε-benzyloxycarbonyl-L-lysine tert-butyl ester 
• 129388-76-7 N^α-<1(R)-ethoxycarbonyl-6-(1-benzyloxycarbonyl-4-piperidyl)hexyl>-N^ε-benzyloxycarbonyl-L-lysine tert-butyl ester 
• 120008-84-6 N^α-<1(S)-ethoxycarbonyl-6-(1-benzyloxycarbonyl-4-piperidyl)hexyl>-N^ε-benzyloxycarbonyl-L-lysine tert-butyl ester 

Downstream Products

• 120008-85-7 4-{(R)-6-[(S)-5-Benzyloxycarbonylamino-1-((S)-2-tert-butoxycarbonyl-pyrrolidine-1-carbonyl)-pentylamino]-6-ethoxycarbonyl-hexyl}-piperidine-1-carboxylic acid benzyl ester 
• 120008-85-7 N^α-<1(S)-ethoxycarbonyl-6-(1-benzyloxycarbonyl-4-piperidyl)hexyl>-N^ε-benzyloxycarbonyl-L-lysyl-L-proline tert-butyl ester 

Relevant academic research and scientific papers

Synthesis and angiotensin converting enzyme inhibitory activity of N-carboxymethyldipeptides with ω-(4-piperidyl)alkyl group

The synthesis of a series of novel, potent angiotensin converting enzyme (ACE) inhibitors containing 1(S)-carboxy-ω-(4-piperidyl)alkyl group at the N-terminal of the dipeptide is described. These 1-carboxy-ω-(4-piperidyl)alkyl derivatives possess greater or equivalent in vitro potency and in vivo efficacy than captopril and enalapril. The length (n) of the carbon chain in the ω-(4-piperidyl)alkyl moiety was varied from two to six to investigate the optimal structure for long-acting ACE inhibitors. 1-[N-[1(S)-Carboxy-6-(4-piperidyl)hexyl]-L-alanyl]-(2α,3aβ,7aβ)-oct ahydro-1H-indole-2-carboxylic acid, the most potent member of the series, had an in vivo area under the curve (AUC) of 685, which was calculated by the inhibition of angiotensin I-induced pressor response vs. time curves (0 to 8 h) after p.o. administration.